Reconstitution: Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.
Description: Recombinant 2019-nCoV Spike S1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val11-Arg682) of 2019-ncov Spike S1 (Accession #YP_009724390.1) fused with an Fc, 6xHis tag at the C-terminus.
Purity: > 95% by SDS-PAGE
Endotoxin: < 1.0 EU/µg of the protein by LAL method
Bioactivity: Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human ACE2 at 2 µg/mL (100 µL/well) can bind Recombinant 2019-nCoV Spike S1-TEVS-hFc-His with a linear range of 78-82.5 ng/mL.
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold symptoms to severe effects including death and respiratory distress. SARS-CoV-2 Spike Protein is composed of S1 domain and S2 domain (Spike Protein). The Spike protein is the main surface antigen of the coronavirus. The glycosylated Spike protein (as well as the nucleocapsid protein) can be detected in infected cell culture supernatants with antisera from SARS patients. S1 contains a receptor-binding domain (RBD) that can specifically bind to angiotensin-converting enzyme 2 (ACE2), the receptor on target cells. CoV diversity is reflected in the variable Spike proteins (S proteins), which have evolved into forms differing in their receptor interactions and their response to various environmental triggers of virus-cell membrane fusion.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: Coronavirus; COVID; Covid 19; COVID-19; COVID19; SARS; SARS Coronavirus; SARS CoV; SARS CoV-2; SARS CoV2; SARS Spike Protein; SARS-CoV-2; SARS-CoV2